New Delhi: Cannabics Pharmaceuticals Inc, recently announced that it has filed a provisional patent application with the US Patent office.
The patent covers the Company’s technology that will enable the transfer of data from its proprietary personalization platform of cannabis strains and cancer to medical cannabis businesses worldwide and overcome the limitations of exporting and importing cannabinoid compounds due to regulation.
Dr Eyal Ballan, Co-Founder and CTO, said: “The idea of creating a large database and translating it to the big variety of strains and compounds worldwide is our way to create standardization in a multifactorial drug like cannabis. It gives us the leverage to enjoy the beneficial facets of the entourage effect while building a matrix of logic behind compound ratios and dosages. We are currently looking for joint ventures that will exercise this ability and implement the technology to identify and create cannabis strains that target cancer.”
Headquartered in Tel-Aviv, Israel, Cannabics Pharmaceuticals Inc. is a US public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile.